{
  "fda": [
    {
      "commentary": "",
      "companies": [
        {
          "cik": "",
          "id": "62b3773a118ebc0001427b67",
          "name": "Alpha Tau Medical Ltd.",
          "securities": [
            {
              "exchange": "NASDAQ",
              "symbol": "DRTS"
            }
          ]
        }
      ],
      "created": 1767621777,
      "date": "2026-01-05",
      "drug": {
        "generic": false,
        "id": "62b3771c9c3cd100011418ce",
        "indication_symptom": [
          "Prostate cancer"
        ],
        "name": "Alpha DaRT"
      },
      "event_type": "Provided Update",
      "id": "695bc49183cac20001bec514",
      "nic_number": "",
      "notes": "",
      "outcome": "Alpha Tau Medical Ltd.  announced the submission of the first module of its pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA), following the FDA's previous decision to allow the Company to use the more flexible modular approach.",
      "outcome_brief": "",
      "source_link": "https://www.benzinga.com/pressreleases/26/01/g49690927/alpha-tau-submits-first-pre-market-approval-module-to-the-fda-for-alpha-dart-for-the-treatment-of-",
      "source_type": "Press Release",
      "status": "",
      "target_date": "",
      "time": "09:00:00",
      "updated": 1767621823
    }
  ]
}